Efficacy of immunosuppression monotherapy after liver transplantation: A meta-analysis

World Journal of Gastroenterology

Volumn 20, Issue 34, 2014, Pages 12330-12340

  Lan, Xiang ^a   Liu, Meng Gang ^a   Chen, Hong Xu ^a   Liu, Hong Ming ^a   Zeng, Wei ^a   Wei, Dong ^a   Chen, Ping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytomegalovirus; Diabetes; Immunosuppression monotherapy; Liver transplantation; Meta analysis

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ARTICLE; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; DRUG EFFECTS; GRAFT SURVIVAL; HEPACIVIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; TIME; TREATMENT OUTCOME; VIROLOGY;

CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RECURRENCE; STEROIDS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909595160     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i34.12330     Document Type: Article

References (45)

1. Bonaccorsi-Riani E, Sempoux C, Piette N, Julliard O, Kabamba B, Ciccarelli O, Roggen F, De Reyck C, Hassoun Z, Lerut J. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up. Acta Gastroenterol Belg 2012; 75: 411-418 [PMID: 23402084]
2. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60: 1057-1060 [PMID: 7491685]
3. Jindal RM, Sidner RA, Hughes D, Pescovitz MD, Leapman SB, Milgrom ML, Lumeng L, Filo RS. Metabolic problems in recipients of liver transplants. Clin Transplant 1996; 10: 213-217 [PMID: 8664522]
4. Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, Hatakeyama K, Ichida T, Kanematsu T, Kitajima M, Kiyosawa K, Makuuchi M, Miyagawa S, Satomi S, Soejima Y, Takada Y, Tanaka N, Teraoka S, Monden M. Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan. Clin Transplant 2012; 26: 857-867 [PMID: 22507465 DOI: 10.1111/j.1399-0012.2012.01627.x]
5. Goddard S, Adams DH. Methylprednisolone therapy for acute rejection: too much of a good thing? Liver Transpl 2002; 8: 535-536 [PMID: 12037784]
6. Martínez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benítez C, Pons JA, Parrilla P, Ramírez P, Bruguera M, Rimola A, Sánchez-Fueyo A. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857 [PMID: 18654667]
7. Margarit C, Martínez Ibañez V, Tormo R, Infante D, Iglesias H. Maintenance immunosuppression without steroids in pediatric liver transplantation. Transplant Proc 1989; 21: 2230-2231 [PMID: 2652721]
8. Padbury RT, Gunson BK, Dousset B, Hubscher SG, Buckels JA, Neuberger JM, Elias E, McMaster P. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789-794 [PMID: 8475553 DOI: 10.1097/00007890-199304000-00020]
9. Dunn SP, Falkenstein K, Lawrence JP, Meyers R, Vinocur CD, Billmire DF, Weintraub WH. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation 1994; 57: 544-547 [PMID: 8116039 DOI: 10.1097/00007890-199402270-00012]
10. Fraser GM, Grammoustianos K, Reddy J, Rolles K, Davidson B, Burroughs AK. Long-term immunosuppression without corticosteroids after orthotopic liver transplantation: a positive therapeutic aim. Liver Transpl Surg 1996; 2: 411-417 [PMID: 9346686]
11. Stegall MD, Everson GT, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R, Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997; 25: 173-177 [PMID: 8985286 DOI: 10.1002/hep.510250132]
12. Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K, Davidson BR, Patch DW, Burroughs AK. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 2006; 8: 3-12 [PMID: 16623815 DOI: 10.1111/j.1399-3062.2006.00124.x]
13. Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005; 18: 1336-1345 [PMID: 16297052 DOI: 10.1111/j.1432-2277.2005.00217.x]
14. Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-1791 [PMID: 19938143]
15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from: URL: http://www.cochrane-handbook.org
16. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B. Cochrane Hepato-biliary Group: About The Cochrane Collaboration (Cochrane Review Groups [CRGs]). The Cochrane Library, 2008 (1): LIVER. Available from: URL: http://onlinelibrary.wiley.com/cochranelibrary/search
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797]
18. Benítez CE, Puig-Pey I, López M, Martínez-Llordella M, Lozano JJ, Bohne F, Londoño MC, García-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sánchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10: 2296-2304 [PMID: 20883560]
19. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61-67 [PMID: 15690537]
20. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90: 1562-1566 [PMID: 21048536 DOI: 10.1097/TP.0b013e3181ff8794]
21. Chau TN, Quaglia A, Rolles K, Burroughs AK, Dhillon AP. Histological patterns of rejection using oral microemulsified cyclosporine and tacrolimus (FK506) as monotherapy induction after orthotopic liver transplantation. Liver 2001; 21: 329-334 [PMID: 11589769 DOI: 10.1034/j.1600-0676.2001.210505.x]
22. Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, Kraemer I, Otto G. Tacrolimus monotherapy without steroids after liver transplantation - a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007; 7: 1616-1623 [PMID: 17511685]
23. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399 [PMID: 12717237]
24. Belli LS, de Carlis L, Rondinara G, Alberti AB, Bellati G, De Gasperi A, Forti D, Idèo G. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998; 27: 1524-1529 [PMID: 9620322 DOI: 10.1002/hep.510270609]
25. De Carlis L, Belli LS, Rondinara GF, Alberti A, Sansalone CV, Colella G, Aseni P, Slim AO, Forti D. Early steroid withdrawal in liver transplant patients: final report of a prospective randomized trial. Transplant Proc 1997; 29: 539-542 [PMID: 9123120 DOI: 10.1016/S0041-1345(96)00255-2]
26. Romani F, Belli LS, De Carlis L, Rondinara GF, Alberti A, Sansalone CV, Bellati G, Zavaglia C, Fesce E, Ideo G. Cyclosporin monotherapy (after 3 months) in liver transplant patients: a prospective randomized trial. Transplant Proc 1994; 26: 2683-2685 [PMID: 7940840]
27. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591 [PMID: 11558484]
28. Schmeding M, Kiessling A, Neuhaus R, Heidenhain C, Bahra M, Neuhaus P, Neumann UP. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation 2011; 92: 923-929 [PMID: 21832958]
29. Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, Varo-Pérez E. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma. Transplant Proc 2011; 43: 711-713 [PMID: 21486580]
30. Manzia TM, Sforza D, Angelico R, Bellini MI, Ciano P, Manuelli M, Toti L, Tisone G. Everolimus and enteric-coated mycophenolate sodium ab initio after liver transplantation: midterm results. Transplant Proc 2012; 44: 1942-1945 [PMID: 22974878 DOI: 10.1016/j.transproceed.2012.06.028]
31. van Hoek B, de Rooij BJ, Verspaget HW. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol 2012; 26: 61-72 [PMID: 22482526 DOI: 10.1016/j.bpg.2012.01.004]
32. Tinti F, Mitterhofer AP, Muiesan P. Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors. Minerva Chir 2012; 67: 1-13 [PMID: 22361672]
33. Andrews WS, Shimaoka S, Sommerauer J, Moore P, Hudgins P. Steroid withdrawal after pediatric liver transplantation. Transplant Proc 1994; 26: 159-160 [PMID: 8108919]
34. Ghio L, Tarantino A, Edefonti A, Mocciaro A, Giani M, Guerra L, Berardinelli L, Vegeto A. Advantages of cyclosporine as sole immunosuppressive agent in children with transplanted kidneys. Transplantation 1992; 54: 834-838 [PMID: 1440850 DOI: 10.1097/00007890-199211000-00013]
35. Li H, Zhang J, He JW, Wang K, Wang GS, Jiang N, Fu BS, Wang GY, Yang Y, Chen GH. Symptomatic osteonecrosis of the femoral head after adult orthotopic liver transplantation. Chin Med J (Engl) 2012; 125: 2422-2426 [PMID: 22882914]
36. Charco R, Bilbao I, Chavez R, Castells LI, Hidalgo E, Margarit C. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. Transplant Proc 2002; 34: 1555-1556 [PMID: 12176482 DOI: 10.1016/S0041-1345]
37. Reding R, Gras J, Bourdeaux C, Wieers G, Truong QD, Latinne D, Sokal E, Janssen M, Lerut J, Otte JB, de Ville de Goyet J. Stepwise minimization of the immunosuppressive therapy in pediatric liver transplantation. A conceptual approach towards operational tolerance. Acta Gastroenterol Belg 2005; 68: 320-322 [PMID: 16268418]
38. Mukherjee S, Botha JF, Mukherjee U. Immunosuppression in liver transplantation. Curr Drug Targets 2009; 10: 557 [PMID: 19519358 DOI: 10.2174/138945009788488477]
39. Lee JH, Lee SK, Lee HJ, Seo JM, Joh JW, Kim SJ, Kwon CH, Choe YH. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J 2009; 50: 784-788 [PMID: 20046418]
40. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751 [PMID: 12499891 DOI: 10.1097/00007890-200212270-00017]
41. Zieniewicz K, Patkowski W, Nyckowski P, Alsharabi A, Michałowicz B, Pawlak J, Paluszkiewicz R, Wróblewski T, Najnigier B, Smoter P, Hevelke P, Skwarek A, Remiszewski P, Kotulski M, Skalski M, Paczek L, Krawczyk M. Results of liver transplantation for hepatocellular cancer. Ann Transplant 2007; 12: 11-14 [PMID: 17953137]
42. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, Fernandez JR, Pijoan I, Testillano M, Suarez MJ, Montejo M, Ortiz de Urbina J. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010; 42: 660-662 [PMID: 20304217 DOI: 10.1016/j.transproceed.2010.02.014]
43. Matsuno N, Iwamoto H, Nakamura Y, Hama K, Kihara Y, Konno O, Jojima Y, Akashi I, Mijiti A, Ashizawa T, Nagao T. ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2008; 40: 2497-2500 [PMID: 18929778 DOI: 10.1016/j.transproceed.2008.07.054]
44. Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant 2011; 16: 14-18 [PMID: 21716180]
45. Berardinelli L, Raiteri M, Ghio L, Messa PG, Montagnino G. The role of immunosuppression in malignancies among 351 pediatric renal transplant patients. Transplant Proc 2010; 42: 1166-1168 [PMID: 20534251 DOI: 10.1016/j.transproceed.2010.03.131]